The US Food and Drug Administration announced on Friday that it has approved Astrazeneca (AZN.US)'s FluMist nasal spray flu vaccine for self-injection, making it the first of its kind.

Regulatory agencies stated that FluMist is the first vaccine for preventing the flu that does not require administration by medical care providers. The company plans to offer FluMist through third-party online pharmacies, where customers must complete screening and eligibility assessments when ordering.